NASDAQ$ATAI
AtaiBeckley Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Atai reported positive net income and pipeline advancements.
Atai Life Sciences reported a net income of $44.2 million for Q3 2023, driven by a non-cash change in the fair value of investments. The company highlighted progress in its clinical programs, including the ongoing Phase 2b study of RL-007 and Phase 1 results from the VLS-01 study.
- Phase 2b study of RL-007 in CIAS patients is on track to report data in 2H 2024.
- Phase 1 data of VLS-01 demonstrated comparable exposure levels to IV DMT.
- Three non-clinical poster presentations were accepted at upcoming medical meetings.
- Cash position of $209M and committed term loan funding are expected to fund operations into 1H 2026.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$87K
Forward guidance
Atai Life Sciences is focused on advancing its clinical programs and expects to report key data milestones in the near future. They anticipate the Phase 2b readout of RL-007 in the second half of 2024 and initial results of the Phase 1 study of EMP-01 later this year.
Tailwinds
- Phase 2b study of RL-007 is on track to report data in 2H 2024.
- Phase 1 data of VLS-01 showed promising results.
- Acquisition of DemeRx IB streamlines operations for DMX-1002 development.
- Initial results of the Phase 1 study of EMP-01 are expected later this year.
- Company's cash position is expected to fund operations into 1H 2026.
Headwinds
- Clinical and preclinical development is uncertain, programs may experience delays.
- Reliance on third parties for clinical trials poses risks.
- Regulatory reviews and approvals are necessary prior to commercialization.
- R&D of drugs targeting the CNS is difficult to predict.
- Significant competition exists in the mental health treatment market.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro